HC
AQST icon

Hurley Capital’s Aquestive Therapeutics AQST Stock Holding History

Hurley Capital’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,569
Closed -$10.1K – 679
2025
Q4 		$10.1K Hold
1,569
– – 0.01% 330
2025
Q3 		$8.77K Hold
1,569
– – ﹤0.01% 378
2025
Q2 		$5.19K Hold
1,569
– – ﹤0.01% 366
2025
Q1 		$4.55K Hold
1,569
– – ﹤0.01% 383
2024
Q4 		$5.62K Buy
+1,569
New +$7.24K ﹤0.01% 323

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hurley Capital's AQST Position: Q1 2026 in Review

Hurley Capital sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 1,569 shares — an estimated $10.1K sold.

Hurley Capital first reported a position in AQST in Q4 2024 and held it in 5 quarters. The position peaked at $10.1K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Hurley Capital reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hurley Capital sold 1,569 Aquestive Therapeutics shares in Q1 2026, an estimated $10.1K.
  • Hurley Capital first reported a position in Aquestive Therapeutics in Q4 2024 and held it in 5 quarters.
  • Hurley Capital's Aquestive Therapeutics position peaked at $10.1K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.